NCT01741844View on ClinicalTrials.gov

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

CompletedOBSERVATIONAL
Enrollment

57

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Acquired Immune Deficiency Syndrome
Interventions
DRUG

No intervention

This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).

Trial Locations (1)

Unknown

Daegu

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01741844 - A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence | Biotech Hunter | Biotech Hunter